192 related articles for article (PubMed ID: 27698247)
1. The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
Ahmad H; Taylor BV; van der Mei I; Colman S; O'Leary BA; Breslin M; Palmer AJ
Mult Scler; 2017 Jul; 23(8):1157-1166. PubMed ID: 27698247
[TBL] [Abstract][Full Text] [Related]
2. Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument.
Ahmad H; van der Mei I; Taylor BV; Campbell JA; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102358. PubMed ID: 32650122
[TBL] [Abstract][Full Text] [Related]
3. Health Utilities for Multiple Sclerosis.
Hawton A; Green C
Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
[TBL] [Abstract][Full Text] [Related]
4. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.
Orme M; Kerrigan J; Tyas D; Russell N; Nixon R
Value Health; 2007; 10(1):54-60. PubMed ID: 17261116
[TBL] [Abstract][Full Text] [Related]
5. Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.
Fogarty E; Walsh C; Adams R; McGuigan C; Barry M; Tubridy N
Mult Scler; 2013 Aug; 19(9):1190-6. PubMed ID: 23401128
[TBL] [Abstract][Full Text] [Related]
6. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Glaspole I; Moodley Y; Goh N; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2021 Sep; 30(9):2615-2632. PubMed ID: 33999322
[TBL] [Abstract][Full Text] [Related]
7. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
[TBL] [Abstract][Full Text] [Related]
8. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.
Naci H; Fleurence R; Birt J; Duhig A
J Med Econ; 2010 Mar; 13(1):78-89. PubMed ID: 20047364
[TBL] [Abstract][Full Text] [Related]
9. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.
Takemoto ML; Lopes da Silva N; Ribeiro-Pereira AC; Schilithz AO; Suzuki C
Health Qual Life Outcomes; 2015 Aug; 13():119. PubMed ID: 26246238
[TBL] [Abstract][Full Text] [Related]
10. Exploring health state utility values of parents of children with a serious illness.
Majmudar IK; Engel L; Muscara F; Stevenson C; McCarthy M; Anderson V; Mihalopoulos C
Qual Life Res; 2020 Jul; 29(7):1947-1959. PubMed ID: 32335816
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
[TBL] [Abstract][Full Text] [Related]
12. A reference set of Health State Utility Values for gambling problem behaviour, a survey of the Australian general population: implications for future healthcare evaluations.
Moayeri F
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):115-124. PubMed ID: 31003582
[No Abstract] [Full Text] [Related]
13. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
14. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
15. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.
Karampampa K; Gustavsson A; van Munster ET; Hupperts RM; Sanders EA; Mostert J; Sinnige OL; de Graaf J; Pop P; Miltenburger C; Groot MT; Relleke M; van der Hel WS
J Med Econ; 2013 Jul; 16(7):939-50. PubMed ID: 23692584
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
17. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
18. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.
Versteegh M
Pharmacoeconomics; 2016 Nov; 34(11):1133-1144. PubMed ID: 27282692
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
20. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
